MAP2K7 and neuroblastoma: Based on the accumulating evidence for MAPK pathway involvement in neuroblastoma, we hypothesized that transcriptional mediators of the Ras-MEK-ERK pathway, specifically ETS-related transcription factors [12], [13] may represent a new target class for high-risk neuroblastoma.